MDEA

Fatal arrhythmias documented in MDEA/MDMA users with underlying cardiac disease. The Dowling et al. (1987) JAMA case series identified cardiac arrhythmia as the probable mechanism of death in three of five fatalities. Any history of arrhythmia, structural heart disease, or prolonged QT interval constitutes an absolute contraindication.

The sympathomimetic cardiovascular effects of MDEA (tachycardia, hypertension) documented in the Gouzoulis (1993) study pose heightened risk in individuals with long QT syndrome. No MDEA-specific QT data exist, but the mechanism is well-established for sympathomimetic stimulants.

Personal history of psychotic disorders (schizophrenia, schizoaffective disorder) or active psychosis constitutes a relative contraindication. No MDEA-specific psychiatric case reports exist; risk inferred from MDxx class pharmacology.

Significant hepatic impairment may reduce MDEA metabolism via CYP3A4 and CYP2D6, leading to elevated plasma concentrations and prolonged effects. Hepatotoxicity is listed as an MDxx class adverse effect. This is a relative contraindication based on metabolic pathway data.

Pregnancy is an absolute contraindication. No MDEA-specific reproductive toxicity data exist, but the compound's monoamine-releasing activity, sympathomimetic cardiovascular effects, and hyperthermia potential all pose risks to fetal development.

Concurrent or recent use of any monoamine oxidase inhibitor (phenelzine, tranylcypromine, selegiline, moclobemide, isocarboxazid) is an absolute contraindication. The MAOI-serotonin releasing agent interaction is among the most lethal known drug combinations. A washout period appropriate to the specific MAOI is required.